Description
MEXAPAN DSR combines Pantoprazole Gastro-Resistant 40 mg with Domperidone Prolonged-Release 30 mg in a capsule formulation. Pantoprazole reduces gastric acid secretion, while Domperidone has prokinetic activity and supports upper gastrointestinal motility. This combination is used in selected gastrointestinal conditions under medical supervision. Pantoprazole is a proton pump inhibitor that suppresses the final step of gastric acid production.
For related gastrointestinal formulations and other pharmaceutical products, explore the Medhexa Pharma product range.
Therapeutic Segment
Gastrointestinal Care | Acid-Related Disorders | GERD Management | Proton Pump Inhibitors | Prokinetic Therapy
Uses of MEXAPAN DSR
MEXAPAN DSR may be prescribed for selected acid-related gastrointestinal conditions where acid suppression together with gastrointestinal motility support is considered appropriate.
Potential clinical uses may include:
- Gastroesophageal reflux disease (GERD)
- Acid reflux and associated heartburn
- Acid-related upper gastrointestinal symptoms
- Selected gastrointestinal symptoms requiring acid suppression and prokinetic therapy
- Conditions where a healthcare professional considers the combination clinically appropriate
The exact indication and treatment duration should depend on the patient’s diagnosis, clinical response and prescribing information.
Key Benefits of MEXAPAN DSR
MEXAPAN DSR combines two active ingredients with complementary gastrointestinal actions:
- Pantoprazole 40 mg helps reduce gastric acid production.
- Domperidone 30 mg prolonged-release provides a prolonged-release form of the prokinetic component.
- The combination provides acid suppression together with gastrointestinal motility support.
- The capsule formulation allows convenient oral administration.
- Supplied in 10 × 10 ALU-ALU packaging.
Pantoprazole directly inhibits the gastric proton pump responsible for the final stage of acid secretion.
How MEXAPAN DSR Works
Pantoprazole belongs to the proton pump inhibitor (PPI) class. It binds to the H⁺/K⁺-ATPase enzyme system in gastric parietal cells and suppresses both basal and stimulated gastric acid secretion. As a result, it reduces the amount of acid released into the stomach.
Domperidone acts mainly by blocking dopamine receptors and can promote upper gastrointestinal motility. It also has antiemetic activity. However, its use requires careful consideration because Domperidone can affect cardiac electrical activity and may prolong the QT interval.
Therefore, MEXAPAN DSR combines gastric acid suppression with gastrointestinal motility support.
Common Side Effects of MEXAPAN DSR
Some patients may experience side effects while taking Pantoprazole or Domperidone.
Possible effects include:
- Headache
- Nausea
- Abdominal discomfort
- Diarrhea
- Constipation
- Dry mouth
- Dizziness
- Flatulence
- Fatigue
Domperidone may also cause hormonal effects such as increased prolactin levels in some patients.
Side effects can vary between individuals. Contact a healthcare professional if symptoms persist, become severe or cause unusual changes.
Important Safety Information
MEXAPAN DSR should be used only under the guidance of a qualified healthcare professional.
Domperidone requires particular attention to cardiovascular safety. It has been associated with QT-interval prolongation, torsades de pointes, serious ventricular arrhythmias and sudden cardiac death. The risk increases in certain patients, particularly those with underlying cardiac conditions, electrolyte abnormalities, higher exposure, or concomitant medicines that prolong the QT interval or inhibit CYP3A4.
Therefore, inform your healthcare professional if you have:
- Heart rhythm problems
- QT prolongation
- Significant heart disease
- Electrolyte abnormalities
- Severe liver disease
- Kidney impairment
- A history of gastrointestinal bleeding or obstruction
Also tell your healthcare professional about every medicine and supplement you take. In particular, mention medicines that can prolong the QT interval or strongly inhibit CYP3A4.
Domperidone should generally be used at the lowest effective dose for the shortest appropriate duration because of its cardiovascular safety considerations.
Pantoprazole treatment also requires appropriate medical review when used for prolonged periods. Long-term PPI therapy can be associated with certain nutritional and metabolic effects, so follow-up should be based on the patient’s clinical situation.
Pregnant or breastfeeding patients should consult a healthcare professional before using MEXAPAN DSR.
For additional regulatory safety information, refer to the European Medicines Agency information on Domperidone-containing medicines.
Dosage & Administration
Take MEXAPAN DSR exactly as prescribed by your healthcare professional.
The appropriate dose and treatment duration depend on the patient’s condition and response to treatment. Do not change the dose or treatment duration without medical advice.
Swallow the capsule whole with water. Do not crush, chew or open the prolonged-release dosage form unless the approved product information specifically allows it.
Pantoprazole is generally administered before meals, according to the prescribing instructions.
Because this formulation contains Domperidone 30 mg prolonged-release, it should not be combined with other Domperidone-containing medicines unless specifically directed by a healthcare professional.
Do not self-medicate with MEXAPAN DSR for persistent acidity, heartburn or digestive symptoms.
Storage
Store MEXAPAN DSR in a cool, dry place away from excessive heat, moisture and direct sunlight.
Keep the capsules in their original ALU-ALU packaging until use.
Follow the specific storage instructions printed on the product packaging.
Keep out of reach of children.
